O & O Alpan LLC
7
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Molecular and Cellular Mechanisms of Lysosomal Storage Diseases
Role: lead
Investigating Lysosomal Storage Diseases in Minority Groups
Role: lead
Exploration of Immunity in Gaucher Disease
Role: lead
Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta
Role: lead
Investigation of Immune Disorders and Deficiencies
Role: lead
Pregnancy and Birth Outcome in Women With Pompe Disease
Role: lead
Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model
Role: lead
All 7 trials loaded